Agenus Reports Third Quarter 2023 Results
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the third quarter 2023.
- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the third quarter 2023.
- The third quarter 2023 closed with a consolidated cash, cash equivalent and short-term investment balance of $106.3 million, compared to $193.4 million at on December 31, 2022.
- Including non-cash expenses of $28.1 million, we incurred a net loss of $64.5 million for the third quarter.
- For the nine months of 2023, we incurred a net loss of $208.9 million including non-cash expenses of $82 million.